Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

French Innovative Leukemia Organisation

Status and phase: Completed; Phase 3

Conditions: Leukemia, Lymphocytic, Acute

Treatments: Drug: interferon alpha 2a

Study type: Interventional

Funder types: Other

Identifiers

NCT00483132

GOELAL02

Details and patient eligibility

About

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy.

High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).

Full description

Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Enrollment: 232 patients

Sex: All

Ages: 15 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• ALL high risk or low risk or lymphoblastic lymphoma
• age 15-55 years old
• informed consent signed

Exclusion Criteria:

• patients previously treated with a chemotherapy or alpha-interferon
• ALL 3 (burkitt like)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)